Shanghai InnoStar Biotech

Shanghai Innostar Biotech Co., Ltd. (also known as National Shanghai Center for New Drug Safety Evaluation & Research, NCDSER) was founded in 2010. Innostar used to be the Department of Pharmacology & Toxicology of Shanghai Institute of Pharmaceutical Industry, which was founded in 1973. The company was one of first four certified GLP agencies in China. Shanghai Innostar now has laboratory and animal facilities of 18,000 square meters, with over 350 research staff. The company provides a range of research services for drug development, including nonclinical safety evaluation, nonclinical pharmacokinetics, bioanalysis, biomarker analysis, and consulting services for drug registration. The company has worked with more than 340 pharmaceutical companies and drug development institutes, and completed over 4,000 research studies, which have been submitted to regulators in China, United States, the member states of the European Union, South Korea, Australia and et.al.. Haimen InnoStar, a wholly-owned subsidiary of Shanghai InnoStar, started operation in 2018. Haimen InnoStar has 30,000 square meters of lab andanimalfacility. Besides safety evaluation and Pharmacokinetics services, Haimen InnoStar also provides druggability assessment, radioactive-labeling and imaging, pharmacodynamics services.